Filing Details
- Accession Number:
- 0001140361-14-025611
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-13 16:16:21
- Reporting Period:
- 2014-06-11
- Filing Date:
- 2014-06-13
- Accepted Time:
- 2014-06-13 16:16:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1428522 | Radius Health Inc. | RDUS | Blank Checks (6770) | 800145732 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1575748 | Katherine Priestley | Suite 6, Albion Riverside Building 8 Hester Road London X0 SW11 4AX | No | No | Yes | No | |
1575753 | Ltd Capital F2 | 3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town Tortola D8 | No | No | Yes | No | |
1600630 | L.p. Iv Bioscience F2 | Po Box 309, Ugland House South Church Street George Town E9 KY1-1104 | No | No | Yes | No | |
1600632 | Ltd. Gp Iv Bioscience F2 | Po Box 309, Ugland House South Church Street George Town E9 KY1-1104 | No | No | Yes | No | |
1600634 | L.p. V Ventures Bio F2 | Kingston Chambers, P.o. Box 173 Road Town Tortola D8 | No | No | Yes | No | |
1600635 | Ltd. Gp Ventures Bio F2 | Kingston Chambers, P.o. Box 173 Road Town Tortola D8 | No | No | Yes | No | |
1600769 | Ltd Holdings Globeways | 3Rd Floor, Geneve Place, Waterfront Dr Po Box 3175, Road Town Tortola D8 | No | No | Yes | No | |
1610441 | L.p. Vi Bioscience F2 | Po Box 309, Ugland House South Church Street George Town E9 KY1-1104 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-06-11 | 1,794,983 | $0.00 | 1,794,983 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2014-06-11 | 871,851 | $0.00 | 871,851 | No | 4 | C | Indirect | See footnote |
Common Stock | Acquisiton | 2014-06-11 | 587,500 | $8.00 | 587,500 | No | 4 | P | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | C | Indirect | See footnote |
No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B-2 Convertible Preferred Stock | Disposition | 2014-06-11 | 227,938 | $0.00 | 1,794,983 | $0.00 |
Common Stock | Series B-2 Convertible Preferred Stock | Disposition | 2014-06-11 | 110,713 | $0.00 | 871,851 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Indirect |
Footnotes
- The securities reported reflect (i) the total number of shares of common stock issued pursuant to the conversion of Series B-2 Convertible Preferred Stock (the "Series B-2 Stock") previously reported, (ii) a 1 for 2.28 reverse stock split, effected by the Issuer on 4/24/14 (the "Stock Split"), and (iii) all accrued dividends on the Series B-2 Stock paid in shares of common stock in connection with such conversion.
- The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Science"). F2 IV GP is the General Partner of F2 Science. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- Prior to its automatic conversion into common stock upon the closing of the Issuer's initial public offering on June 11, 2014 (the "Closing Date"), the Series B-2 Stock was convertible at any time, at the holder's election and had no expiration date. On the Closing Date, the Series B-2 Stock was automatically converted into common stock on a 4.386 to 1 basis (which conversion ratio is reflective of the Stock Split), plus accrued dividends on the Series B-2 Stock payable in shares of common stock in connection with such conversion.